Expanded Access Program | List of Frontiers open access articles

Brief Research Report

Published on 03 Mar 2021

Cannabidiol in Pharmacoresistant Epilepsy: Clinical Pharmacokinetic Data From an Expanded Access Program

in Neuropharmacology

Manuela Contin
Susan Mohamed
Margherita Santucci
Monica Anna Maria Lodi
Emilio Russo
Oriano Mecarelli
CBD LICE Italy Study Group

Frontiers in Pharmacology

doi 10.3389/fphar.2021.637801

7,527 views
28 citations

Perspective

Published on 09 Oct 2023

Taking AIM at serious illness: implementing an access to investigational medicines expanded access program

in Regulatory Science

Meghan Morrison Joly
Terri L. Edwards
Rebecca N. Jerome
Alex Mainor
Gordon R. Bernard
Jill M. Pulley

Frontiers in Medicine

doi 10.3389/fmed.2023.1287449

2,861 views
1 citation

Original Research

Published on 20 May 2021

Results From an Italian Expanded Access Program on Cannabidiol Treatment in Highly Refractory Dravet Syndrome and Lennox–Gastaut Syndrome

in Epilepsy

Luigi Francesco Iannone
Gabriele Arena
Domenica Battaglia
Francesca Bisulli
Paolo Bonanni
Antonella Boni
Maria Paola Canevini
Gaetano Cantalupo
Elisabetta Cesaroni
Manuela Contin

Frontiers in Neurology

doi 10.3389/fneur.2021.673135

9,177 views
43 citations

Original Research

Published on 03 Jun 2024

Avelumab first-line maintenance treatment in patients with locally advanced or metastatic urothelial carcinoma: real-world results from a Korean expanded access program

in Genitourinary Oncology

Se Hoon Park
Sang Joon Shin
Sun Young Rha
Seung-Hoon Beom
Ho Kyung Seo
Bhumsuk Keam
Miso Kim
Yoon-Hee Hong
Shinkyo Yoon
Jae-Lyun Lee

Frontiers in Oncology

doi 10.3389/fonc.2024.1403120

3,887 views
10 citations

Original Research

Published on 25 Aug 2015

Sunitinib in Metastatic Renal Cell Carcinoma: A Systematic Review of UK Real World Data

in Genitourinary Oncology

Miriam Argyropulo-Palmer
Aaron Jenkins
Davinder Singh Theti
James Larkin
David Montgomery

Frontiers in Oncology

doi 10.3389/fonc.2015.00195

6,930 views
7 citations

Original Research

Published on 09 Jan 2019

A Care Process Model to Deliver 177Lu-Dotatate Peptide Receptor Radionuclide Therapy for Patients With Neuroendocrine Tumors

in Radiation Oncology

Pashtoon Murtaza Kasi
Catherine L. Maige
Faisal Shahjehan
Jessica M. Rodgers
Debora L. Aloszka
Ashton Ritter
Margaret L. Andrus
Jessica M. Mcmillan
Kabir Mody
Akash Sharma

Frontiers in Oncology

doi 10.3389/fonc.2018.00663

14,924 views
7 citations

Original Research

Published on 22 Oct 2025

Durvalumab following definitive chemoradiotherapy among patients with stage III NSCLC in the Thai population: a real-world, multicenter observational study

in Thoracic Oncology

Piyada Sitthideatphaiboon
Thanyanan Reungwetwattana
Sureerat Jaruhathai
Archara Supavavej
Piyarat Limpawittayakul
Kunlatida Maneenil
Krittiya Korphaisarn
Thatthan Suksombooncharoen
Luangyot Thongthieang
Chirawadee Sathitruangsak

Frontiers in Oncology

doi 10.3389/fonc.2025.1647385

1,626 views

Articles

Cannabidiol in Pharmacoresistant Epilepsy: Clinical Pharmacokinetic Data From an Expanded Access Program

Taking AIM at serious illness: implementing an access to investigational medicines expanded access program

Results From an Italian Expanded Access Program on Cannabidiol Treatment in Highly Refractory Dravet Syndrome and Lennox–Gastaut Syndrome

Avelumab first-line maintenance treatment in patients with locally advanced or metastatic urothelial carcinoma: real-world results from a Korean expanded access program

Sunitinib in Metastatic Renal Cell Carcinoma: A Systematic Review of UK Real World Data

A Care Process Model to Deliver 177Lu-Dotatate Peptide Receptor Radionuclide Therapy for Patients With Neuroendocrine Tumors

Durvalumab following definitive chemoradiotherapy among patients with stage III NSCLC in the Thai population: a real-world, multicenter observational study